<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Autosomal recessive nucleotide excision repair disorders exhibiting cutaneous photosensitivity</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Autosomal recessive nucleotide excision repair disorders exhibiting cutaneous photosensitivity</h1>
<div class="graphic"><div class="figure"><div class="ttl">Autosomal recessive nucleotide excision repair disorders exhibiting cutaneous photosensitivity</div><div class="cntnt"><table cellspacing="0"><colgroup width="25%"></colgroup><colgroup width="15%"></colgroup><colgroup width="60%"></colgroup> <tbody> <tr> <td class="subtitle1">Phenotype</td> <td class="subtitle1">Gene(s)</td> <td class="subtitle1">Clinical features</td> </tr> <tr class="divider_bottom"> <td>COFS syndrome<br/> (Pena-Shokeir syndrome, type II; OMIM PS214150) </td> <td class="centered"><em>ERCC2</em><br/> <em>ERCC5</em><br/> <em>ERCC6</em> </td> <td> <ul> <li>Progressive neurologic disorder marked by microcephaly with intracranial calcifications and growth failure. </li> <li>Ocular findings of microcornea, cataracts, and optic atrophy are present along with congenital joint contractures. </li> <li>Photosensitivity may occur with a concurrent cellular phenotype of UV sensitivity. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td>CS</td> <td class="centered"><em>ERCC6</em><br/> <em>ERCC8</em> </td> <td> <ul> <li>CS type I – Normal prenatal growth with onset of growth and developmental abnormalities in the first two years. By the time the disease has become fully manifest, height, weight, and head circumference are far below the fifth percentile. Progressive impairment of vision, hearing, and central and peripheral nervous system function lead to severe disability. Death typically occurs in the first or second decade. </li> <li>As in XP, cells from individuals with CS are hypersensitive to killing by UV; however, CS cells have normal post-UV unscheduled DNA synthesis (UDS). CS cells also have delayed recovery of RNA synthesis after UV exposure, reflecting their deficiency in TC-NER. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td>TTD (OMIM PS601675)</td> <td class="centered"><em>ERCC3</em><br/> <em>ERCC2</em><br/> <em>GTF2H5</em><br/> <em>MPLKIP</em><br/> <em>GTF2E2</em> </td> <td> <ul> <li>Variable phenotype including photosensitivity, ichthyosis, brittle hair with "tiger tail" appearance under polarizing microscopy, intellectual impairment, short stature, microcephaly, dysmyelination of the brain, and the characteristic facial features of protruding ears and micrognathia. </li> <li>Twenty-fold increased risk of death before age 10 years, primarily from infections. </li> <li>Frequency of pregnancy complications and neonatal abnormalities is increased in TTD but not in mothers with XP who have different pathogenic variants in the same gene (<em>ERCC2</em>). </li> </ul> </td> </tr> <tr class="divider_bottom"> <td>XP/CS complex</td> <td class="centered"><em>ERCC2</em><br/> <em>ERCC3</em><br/> <em>ERCC4</em><br/> <em>ERCC5</em> </td> <td> <ul> <li>Facial freckling and early skin cancers typical of XP and some features of CS (eg, intellectual disability, spasticity, short stature, hypogonadism) but not skeletal dysplasia. In contrast to XP, in which neuronal degeneration predominates, dysmyelination typical of CS is observed in XP/CS. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td>COFS/TTD</td> <td class="centered"><em>ERCC2</em></td> <td> <ul> <li>Combined features of COFS and TTD </li> </ul> </td> </tr> <tr class="divider_bottom"> <td>CS/TTD complex</td> <td class="centered"><em>ERCC2</em></td> <td> <ul> <li>Combined features of CS and TTD </li> </ul> </td> </tr> <tr class="divider_bottom"> <td>UV-sensitive syndrome</td> <td class="centered"><em>ERCC6</em><br/> <em>ERCC8</em><br/> <em>UVSSA</em> </td> <td> <ul> <li>Mild photosensitivity without pigmentary abnormalities or apparent defects in the central nervous system. Cells from affected individuals have the same transcription defects as those in individuals with CS. </li> </ul> </td> </tr> <tr> <td>XP/TTD complex</td> <td class="centered"><em>ERCC2</em></td> <td> <ul> <li>Phenotypic features of TTD with the clinical and cellular phenotype of XP. Unlike most people with TTD, those with XP/TTD may experience increased frequency of skin cancers. </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">COFS: cerebrooculofacioskeletal; UV: ultraviolet; CS: Cockayne syndrome; XP: xeroderma pigmentosum; TC-NER: transcription-coupled nucleotide excision repair; TTD: trichothiodystrophy.</div><div class="graphic_reference">Adapted from: Kraemer KH, DiGiovanna JJ. Xeroderma pigmentosum, June 20, 2003 [Updated September 29, 2018]. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, Seattle 2003. Available at: <a href="http://www.ncbi.nlm.nih.gov/books/NBK1397/" target="_blank">www.ncbi.nlm.nih.gov/books/NBK1397/</a> (Accessed on April 25, 2018). Copyright © University of Washington 1993-2018. GeneReviews® is a registered trademark of the University of Washington, Seattle. The content is used with permission. All rights reserved.</div><div id="graphicVersion">Graphic 117627 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
